Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;62 Suppl 1(Suppl 1):S7-S11.
doi: 10.1016/j.breast.2022.01.008. Epub 2022 Jan 22.

Breast and axillary surgery after neoadjuvant systemic treatment - A review of clinical routine recommendations and the latest clinical research

André Pfob  1 , Joerg Heil  2
Affiliations
Review

Breast and axillary surgery after neoadjuvant systemic treatment - A review of clinical routine recommendations and the latest clinical research

André Pfob et al. Breast. 2022 Mar.

Abstract

Breast and axillary surgery after neoadjuvant systemic treatment for women with breast cancer has undergone multiple paradigm changes within the past years. In this review, we provide a state-of-the-art overview of breast and axillary surgery after neoadjuvant systemic treatment from both, a clinical routine perspective and a clinical research perspective. For axillary disease, axillary lymph node dissection, sentinel lymph node biopsy, or targeted axillary dissection are nowadays recommended depending on the lymph node status before and after neoadjuvant systemic treatment. For the primary tumor in the breast, breast conserving surgery remains the standard of care. The clinical management of exceptional responders to neoadjuvant systemic treatment is a pressing knowledge gap due to the increasing number of patients who achieve a pathologic complete response to neoadjuvant systemic treatment and for whom surgery may have no therapeutic benefit. Current clinical research evaluates whether less invasive procedures can exclude residual cancer after neoadjuvant systemic treatment as reliably as surgery to possibly omit surgery for those patients in the future.

Keywords: Biopsy; Breast cancer; Intelligent VAB; Neoadjuvant systemic treatment; Pathologic complete response; Surgery.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Heil J., Kuerer H.M., Pfob A., Rauch G., Sinn H.P., Golatta M., et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31:61–71. doi: 10.1016/j.annonc.2019.10.012. - DOI - PubMed
    1. Golshan M., Cirrincione C.T., Sikov W.M., Berry D.A., Jasinski S., Weisberg T.F., et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance) Ann Surg. 2015;262:434–438. doi: 10.1097/SLA.0000000000001417. Lippincott Williams and Wilkins. - DOI - PMC - PubMed
    1. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241. doi: 10.1056/NEJMoa022152. - DOI - PubMed
    1. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232. doi: 10.1056/NEJMoa020989. - DOI - PubMed
    1. Veronesi U., Paganelli G., Galimberti V., Viale G., Zurrida S., Bedoni M., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1996;349:1864–1867. doi: 10.1016/S0140-6736(97)01004-0. - DOI - PubMed

LinkOut - more resources